Literature DB >> 2225696

Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine.

M Depot1, J R Powell, J A Messenheimer, G Cloutier, M J Dalton.   

Abstract

In this double-blind, randomized, crossover, placebo-controlled study, the effect of multiple oral doses of acetaminophen on lamotrigine disposition was examined in healthy volunteers. Eight volunteers received two single 300 mg oral doses of lamotrigine, administered 20 days apart. Acetaminophen (2.7 gm/day) or placebo was taken for 24 hours before and continued for 10 days after each lamotrigine dose. Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen. There was no significant difference in the peak plasma concentration or the time to reach peak plasma concentration. The percentage of the dose of lamotrigine recovered in the urine (total) was significantly higher during the acetaminophen treatment (65.9% +/- 12.3% versus 72.5% +/- 5.7%, p = 0.048). Acetaminophen seems to facilitate lamotrigine removal through a yet to be determined mechanism(s).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225696     DOI: 10.1038/clpt.1990.162

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

Review 1.  Management of focal-onset seizures: an update on drug treatment.

Authors:  Svein I Johannessen; Elinor Ben-Menachem
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Paracetamol: new vistas of an old drug.

Authors:  Alfio Bertolini; Anna Ferrari; Alessandra Ottani; Simona Guerzoni; Raffaella Tacchi; Sheila Leone
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 3.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

4.  Interaction between paracetamol and lamotrigine: new insights from the FDA Adverse Event Reporting System (FAERS) database.

Authors:  Carla Carnovale; Giulia Mosini; Michele Gringeri; Vera Battini; Faizan Mazhar; Marco Pozzi; Emilio Clementi; Sonia Radice
Journal:  Eur J Clin Pharmacol       Date:  2019-06-14       Impact factor: 2.953

Review 5.  Pharmacokinetic interactions of the new antiepileptic drugs.

Authors:  B Rambeck; U Specht; P Wolf
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 6.  Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

7.  Sodium valproate acutely inhibits lamotrigine metabolism.

Authors:  A W Yuen; G Land; B C Weatherley; A W Peck
Journal:  Br J Clin Pharmacol       Date:  1992-05       Impact factor: 4.335

Review 8.  Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.

Authors:  K L Goa; S R Ross; P Chrisp
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

Review 9.  Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy.

Authors:  A Fitton; K L Goa
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine.

Authors:  R D Elwes; C D Binnie
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.